SI
UTHR icon

Symmetry Investments’s United Therapeutics UTHR Stock Holding History

Symmetry Investments’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,101
Closed -$669K – 210
2024
Q2 		$669K Buy
+2,101
New +$556K 0.08% 127
2023
Q1 		– Sell
-16,646
Closed -$4.63M – 157
2022
Q4 		$4.63M Buy
+16,646
New +$4.2M 1.24% 17

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Symmetry Investments's UTHR Position: Q3 2024 in Review

Symmetry Investments sold out of United Therapeutics (UTHR) in Q3 2024, closing a stake of 2,101 shares — an estimated $669K sold.

Symmetry Investments first reported a position in UTHR in Q4 2022 and held it in 2 quarters. The position peaked at $4.63M in Q4 2022. 624 funds tracked by Wall St. Rank hold UTHR as of Q3 2024.

  • Symmetry Investments reported no remaining United Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Symmetry Investments sold 2,101 United Therapeutics shares in Q3 2024, an estimated $669K.
  • Symmetry Investments first reported a position in United Therapeutics in Q4 2022 and held it in 2 quarters.
  • Symmetry Investments's United Therapeutics position peaked at $4.63M in Q4 2022.
  • 624 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2024.

Based on Symmetry Investments's 13F filing for Q3 2024, filed 14 Nov 2024.